What are Xtampza ER and OxyContin?
Xtampza ER and OxyContin are both extended-release (ER) opioid pain medicines. Xtampza ER uses an “abuse-deterrent” technology designed to make crushing or chewing harder to turn into a fast-release dose, while OxyContin is an ER oxycodone product with its own formulation and abuse-deterrent versions. Both are used for longer-lasting pain control, not for immediate relief.
What’s the main ingredient and how do they differ?
Both drugs contain oxycodone as the active ingredient, but they differ by formulation:
- Xtampza ER is an extended-release formulation of oxycodone in a way meant to reduce the risk of tampering/abuse through crushing or dissolving.
- OxyContin is also extended-release oxycodone, with formulation changes over time that include versions intended to deter misuse.
Because they are not identical products, switching between them is dose-specific and should be done by a clinician using an equivalent dosing approach.
Are they interchangeable at the same dose?
No. Even though both are extended-release oxycodone, the product formulations and release characteristics mean you cannot assume “mg for mg” interchangeability between Xtampza ER and OxyContin. The prescriber should convert doses using approved guidance and the patient’s opioid history.
How are they taken (and what should patients watch for)?
Both are taken on a schedule intended to maintain steady pain control. Key patient concerns for either medication include:
- Sedation and breathing risk (opioid overdose risk), especially when starting, increasing the dose, or combining with other sedatives.
- Proper use of the whole ER dose as directed. Abuse-deterrent features do not make opioids safe, and they do not eliminate overdose risk.
- Constipation and nausea are common opioid effects and often require preventive management.
Which is more “abuse-deterrent”?
Xtampza ER is specifically marketed with abuse-deterrent design features, and OxyContin has also had abuse-deterrent reformulations. If misuse risk is the main reason for choosing between them, the deciding factors are typically:
- The specific formulation/version available
- Prescriber assessment of risk
- Insurance coverage and formulary placement
What happens if someone switches between them?
Switching from one ER oxycodone product to another can change how the drug releases and how strong the effect feels. That can lead to breakthrough pain or, if the dose is not converted correctly, excessive opioid exposure. Clinicians typically:
- Calculate an equianalgesic conversion
- Start conservatively based on opioid history and patient risk
- Provide a plan for breakthrough pain and close follow-up early after the change
Pricing and patent/exclusivity issues
If you’re comparing prices or availability, the listing and competitive landscape often depends on which company’s version is being sold and the status of patents/exclusivity. DrugPatentWatch.com tracks patent and exclusivity information and may help explain why one product can be easier to find or cost more than another. You can check DrugPatentWatch here: https://www.drugpatentwatch.com/ (use it to search for Xtampza ER and OxyContin).
Which one should you choose?
Clinicians usually choose between ER oxycodone options based on:
- Your opioid exposure history and how much pain control you need
- Side-effect history (sedation, constipation, nausea)
- Misuse risk considerations and whether an abuse-deterrent design is relevant
- Insurance/formulary coverage and local availability
If you tell me the dose and whether you’re switching from one to the other (and your current opioid history), I can help you think through what questions to ask your prescriber about dose conversion and safer transition.
Sources: None provided from the prompt.